Trade TG Therapeutics, Inc. - TGTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 40.21 |
| Open | 39.47 |
| 1-Year Change | 182.74% |
| Day's Range | 39.47 - 41.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 40.21 | 0.86 | 2.19% | 39.35 | 40.99 | 39.25 |
| Apr 23, 2025 | 39.40 | 0.70 | 1.81% | 38.70 | 40.20 | 38.42 |
| Apr 22, 2025 | 37.92 | 0.39 | 1.04% | 37.53 | 38.45 | 37.41 |
| Apr 21, 2025 | 36.93 | -1.10 | -2.89% | 38.03 | 40.04 | 36.30 |
| Apr 17, 2025 | 38.24 | 0.49 | 1.30% | 37.75 | 38.77 | 37.54 |
| Apr 16, 2025 | 38.16 | -0.54 | -1.40% | 38.70 | 38.82 | 37.26 |
| Apr 15, 2025 | 38.96 | 1.00 | 2.63% | 37.96 | 39.08 | 37.62 |
| Apr 14, 2025 | 38.33 | 1.03 | 2.76% | 37.30 | 38.78 | 36.69 |
| Apr 11, 2025 | 36.63 | 0.58 | 1.61% | 36.05 | 36.72 | 35.17 |
| Apr 10, 2025 | 35.90 | 0.85 | 2.43% | 35.05 | 37.07 | 33.82 |
| Apr 9, 2025 | 35.77 | 1.23 | 3.56% | 34.54 | 37.07 | 30.94 |
| Apr 8, 2025 | 35.48 | -2.77 | -7.24% | 38.25 | 38.75 | 34.79 |
| Apr 7, 2025 | 37.09 | 2.33 | 6.70% | 34.76 | 38.35 | 33.65 |
| Apr 4, 2025 | 37.24 | -0.66 | -1.74% | 37.90 | 38.66 | 36.46 |
| Apr 3, 2025 | 39.30 | 1.34 | 3.53% | 37.96 | 39.96 | 37.96 |
| Apr 2, 2025 | 39.77 | 2.57 | 6.91% | 37.20 | 41.94 | 36.96 |
| Apr 1, 2025 | 37.68 | -1.49 | -3.80% | 39.17 | 39.37 | 37.55 |
| Mar 31, 2025 | 39.33 | 1.07 | 2.80% | 38.26 | 39.51 | 36.43 |
| Mar 28, 2025 | 39.80 | -0.24 | -0.60% | 40.04 | 40.45 | 38.75 |
| Mar 27, 2025 | 40.13 | -0.45 | -1.11% | 40.58 | 40.94 | 39.76 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
TG Therapeutics, Inc. Company profile
About TG Therapeutics Inc
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, TG Therapeutics Inc revenues increased from $152K to $6.7M. Net loss increased 25% to $348.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other general and administrative increase from $41.5M to $90.9M (expense), Other research and development increase of 31% to $198.5M (expense).
Equity composition
Common Stock $.05 Par, 04/12, 500M auth., 5,058,834 issd. Insiders & stakeholders own 39.30%. Preferred Stock $.001 Par, 1.5M auth. 03/08 Company delisted from AMEX to OTC Bulletin Board. 07/11, 1-for-50 reverse stock split. 04/12, 1-for-56.25 Reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
3020 Carrington Mill Blvd., Suite 475
MORRISVILLE
NORTH CAROLINA 27560-5435
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com